1614P PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Ravi A. Madan(National Cancer Institute), Fatima Karzai(National Institutes of Health), Sheri McMahon(National Cancer Institute), Jeanny B. Aragon‐Ching(Inova Fairfax Hospital), Lisa M. Cordes(National Institutes of Health Clinical Center), Amy Hankin(National Institutes of Health), W. Figg(National Cancer Institute), N. Williams(National Cancer Institute), James L. Gulley(National Cancer Institute), Philip M. Arlen(Dana-Farber Cancer Institute), Liza Lindenberg(National Cancer Institute), Peter L. Choyke(National Cancer Institute), Elias Bin Aris Chandran(National Institutes of Health), Yolanda McKinney(National Cancer Institute), Elizabeth Lamping(National Cancer Institute), Chao Chen(Zhengzhou University), Esther Mena Gonzalez(National Cancer Institute)
Cited by 2
Related Papers
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
|Nature Genetics|1997|1.5k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
|Cancer Immunology Research|2015|456
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
|Clinical Cancer Research|2018|415